Novel therapeutic targets and predictive markers for hepatocellular carcinoma

Area of Science:

• Oncology
• Hepatocellular Carcinoma Research
• Drug Development

Background:

• Sorafenib was the first systemic agent approved for advanced hepatocellular carcinoma (HCC).
• Despite sorafenib's approval, many recent drug trials in HCC have yielded limited success.
• There is an ongoing need for novel therapeutic targets and predictive biomarkers for HCC treatment.

Purpose of the Study:

• To review potential novel targets for HCC drug development.
• To examine the rationale behind therapeutic target development.
• To explore the use of predictive biomarkers for patient selection in drug testing.

Main Methods:

• Literature review of potential novel targets for HCC drug development.
• Analysis of the scientific rationale for targeting specific pathways in HCC.
• Evaluation of the role of predictive biomarkers in patient stratification for clinical trials.

Main Results:

• Identification of several promising novel therapeutic targets for HCC.
• Discussion of the potential for predictive biomarkers to guide treatment decisions.
• Emphasis on the need for biomarker-driven approaches in HCC drug development.

Conclusions:

• Future drug development for HCC should move beyond an 'all-comers' approach.
• Clinical trials must prioritize selected populations based on viral etiology and molecular targets.
• Development of targeted agents for HCC necessitates robust biomarker studies and sample acquisition.